Home Intervention for Asthma Is Cost-effective

Published Online: Thursday, December 1, 2005

New data from the National Institutes of Health suggest that home-based environmental intervention programs are cost-effective. A 2-year study, conducted at 7 centers across the United States, was funded by the National Institute of Allergy and Infectious Diseases. The findings showed that such intervention programs greatly help inner-city children who have moderate-to-severe asthma.

The home-based programs were designed to target 6 major classes of allergens that trigger asthma symptoms—dust mites, cockroaches, pet dander, rodents, passive smoking, and mold. The programs featured educational home visits with specific measures for reducing or eliminating allergen levels in the home. The measures included placing impermeable covers on mattresses, box springs, and pillows; installing air purifiers with high-efficiency particulate air (HEPA) filters; using vacuum cleaners with HEPA filters; and professional pest control.

Children who received the intervention had 19% fewer unscheduled clinic visits and a 13% reduction in the use of albuterol inhalers. These children also experienced 38 more symptom-free days over the course of the study than those who did not receive the intervention.

The at-home programs successfully decreased allergen levels in the home and reduced symptoms in asthma patients. The data also showed that the cost of caring for asthma patients would be even lower if these intervention programs were implemented in a community setting, and they would be as cost-effective as many different drug interventions. The results were published in the on-line version of the Journal of Allergy and Clinical Immunology.

Latest Articles
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Latest Issues